基本信息:
- 专利标题: ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY
- 专利标题(中):拮抗白细胞介素-21受体活性
- 申请号:PCT/US2005027912 申请日:2005-08-05
- 公开(公告)号:WO2006135385A3 公开(公告)日:2007-02-22
- 发明人: YOUNG DEBORAH A , COLLINS MARY , DUNUSSI-JOANNOPOULOS KYRIAKI , O'HARA RICHARD MICHAEL JR , KASAIAN MARION T , WHITTERS MATTHEW J
- 申请人: WYETH CORP , YOUNG DEBORAH A , COLLINS MARY , DUNUSSI-JOANNOPOULOS KYRIAKI , O'HARA RICHARD MICHAEL JR , KASAIAN MARION T , WHITTERS MATTHEW J
- 专利权人: WYETH CORP,YOUNG DEBORAH A,COLLINS MARY,DUNUSSI-JOANNOPOULOS KYRIAKI,O'HARA RICHARD MICHAEL JR,KASAIAN MARION T,WHITTERS MATTHEW J
- 当前专利权人: WYETH CORP,YOUNG DEBORAH A,COLLINS MARY,DUNUSSI-JOANNOPOULOS KYRIAKI,O'HARA RICHARD MICHAEL JR,KASAIAN MARION T,WHITTERS MATTHEW J
- 优先权: US59908604 2004-08-05; US63917604 2004-12-23
- 主分类号: A61K39/395
- IPC分类号: A61K39/395 ; A61K38/17 ; A61P37/00 ; C07K19/00 ; C12N5/10 ; C12N15/63
摘要:
Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).
摘要(中):
使用IL-21或IL-21受体(“IL-21R”或“MU-1”)拮抗剂抑制白细胞介素-21(IL-21)/ IL-21受体(MU-1)活性的方法和组合物 披露。 IL-21 / IL-21R拮抗剂可用于在体内诱导免疫抑制,例如用于治疗,改善或预防自身免疫性或炎症性疾病,包括例如炎症性肠病(IBD),类风湿性关节炎 ),移植/移植排斥反应,牛皮癣,哮喘,纤维化和系统性红斑狼疮(SLE)。
IPC结构图谱:
A | 人类生活必需 |
--A61 | 医学或兽医学;卫生学 |
----A61K | 医用、牙科用或梳妆用的配制品 |
------A61K39/00 | 含有抗原或抗体的医药配制品 |
--------A61K39/395 | .抗体;免疫球蛋白;免疫血清,例如抗淋巴细胞血清 |